Search This Blog

Thursday, May 14, 2026

Regenxbio to seek accelerated FDA approval for RGX-202

 

Regenxbio to seek accelerated FDA approval for RGX-202 after AFFINITY DUCHENNE data show 28 of 30 boys ≥10% microdystrophin

  • Fiscal Q1 2026 non-GAAP EPS was $-1.72 (-1533% YoY) on revenue of $6.4M (-93% YoY), missing analyst estimates.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)